4Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections [J]. Future Microbiol,2008, 3 (6) :635-648. DOI: 10. 2217/ 17460913.3.6. 635.
5Waites KB, Bade DJ, Bebear CM, et al. CLSI M43-P-Methods for antimierobial susceptibility testing of human Myeoplasmas; Approved Guideline [ M]. Pennsylvania: Clinical and Laboratory Standard Institute, 2011.
6Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study [J]. PLoS Med, 2013, 10(5): e1001444. DOI:10. 1371/ joumal, pmed. 1001444.
7Yavlovich A, Tarshis M, Rottem S. Internalization and intracellular survival of Mycoplasma pneumoniae by non- phagocytic cells [ J ]. FEMS Microbiol Lett, 2004,233 (2) : 241 - 246. DOI:10. llll/j. 1574-6968. 2004. tb09488, x.
8Daxboeck F, Khanakah G, Bauer C, et al. Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumonia by PCR[J]. Int J Med Microbiol, 2005, 295 (4) : 279-285. DOI: 10. 1016/j. ijmm. 2005.05. 001.
9Bioudi E, McCulloh R, Alverson B, et al. Treatment of Mycoplasma pneumonia: a systematic review [ J ]. Pediatrics, 2014,133 (6) : 1081-1090. DOI : 10. 1542/peds2013-3729.
10Gardiner SJ, Gavranich JB, Chang AB. Antibiotics forcommunity-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children [ J ]. Cochrane Database Syst Rev, 2015, 1: CD004875. DOI: 10. 1002/14651858. CD004875. pub5.
